Scarica l'app Stockscreener
1.08
3.57%
-0.04
Dopo l'orario di chiusura:
1.13
0.05
+4.63%
Precedente Chiudi:
$1.12
Aprire:
$1.14
Volume 24 ore:
121.62K
Relative Volume:
0.24
Capitalizzazione di mercato:
$4.19M
Reddito:
$35.49M
Utile/perdita netta:
$-6.04M
Rapporto P/E:
-0.083
EPS:
-13.0191
Flusso di cassa netto:
$-6.42M
1 W Prestazione:
-2.70%
1M Prestazione:
-11.48%
6M Prestazione:
-90.92%
1 anno Prestazione:
-92.45%
Intervallo 1D:
$1.08
$1.14
Intervallo di 1 settimana:
$1.08
$1.235
Portata 52W:
$1.01
$24.30
Sunshine Biopharma Inc Stock (SBFM) Company Profile
Nome
Sunshine Biopharma Inc
Settore
Telefono
954-330-0684
Indirizzo
333 LAS OLAS WAY, FORT LAUDERDALE
Compare SBFM vs TAK, TEVA, HLN, ZTS, UTHR
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SBFM
Sunshine Biopharma Inc
|
1.08 | 4.34M | 35.49M | -6.04M | -6.42M | -13.02 |
TAK
Takeda Pharmaceutical Co Adr
|
18.11 | 58.15B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
36.35 | 42.94B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.22 | 40.59B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
72.86 | 30.29B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
503.86 | 21.74B | 3.17B | 1.29B | 1.01B | 27.09 |
Sunshine Biopharma Inc Borsa (SBFM) Ultime notizie
Sunshine Biopharma (NASDAQ: SBFM) Anticipates $31M from Series B Warrant Exercises - Kalkine Media
Price to earnings forward of Sunshine Biopharma Inc. – BOATS:SBFMW - TradingView
Price to sales forward of Sunshine Biopharma Inc. – BOATS:SBFMW - TradingView
Sunshine Biopharma Inc. SEC Filing (Sep 9, 2026) - Stock Titan
Sunshine Biopharma receives Canadian approval for atenolol tablets By Investing.com - Investing.com Nigeria
Sunshine Biopharma Announces Board Vacancy as Dr. Andrew Keller Steps Down After Term Ends - Kalkine Media
SBFM Looks 52.9% Undervalued on GF Value™ Despite Weak Fundamentals - GuruFocus
Health Canada Approves Sunshine Biopharma's Atenolol for Treating and Managing Cardiovascular Conditions - Cadillac News
Health Canada approves Atenolol, a drug used for high blood pressure and chest pain - Stock Titan
Sunshine Biopharma (NASDAQ: SBFM) could raise $31M from warrants - Stock Titan
Dr. Andrew Keller to Leave Sunshine Biopharma Board at Term End - TradingView
Sunshine Biopharma Inc. Announces Term Completion of Dr. Andrew Keller as Director - marketscreener.com
Sunshine Biopharma Inc. (SBFM) Shareholding Pattern – Promoters, FIIs & DIIs - valueresearchonline.com
Sunshine Biopharma Inc. (SBFM) Key Financial Ratios – Valuation, Profitability & More - valueresearchonline.com
Sunshine Biopharma Reports In Vivo Tumor Suppression with K1.1 mRNA and Advances Novel mRNA-Cancer Vaccine Strategy for Lung Cancer - The Batesville Daily Guard
Sunshine Biopharma Inc. Warrant (SBFMW) Peer Comparison – Compare with Others - valueresearchonline.com
Sunshine (SBFMW) Market: Closes Nearly Flat at $0.05 in the Available Record; Levels: the Current Price Sits Inside the Supplied Technical RangeExhaustion Gap - vinanet.vn
Sunshine Biopharma wins Canadian approval for generic Enalapril tablets - Bitget
SBFM Looks 55.2% Undervalued on GF Value™ Despite Challenging Fu - GuruFocus
BRIEF-Sunshine Biopharma Receives Canadian Regulatory Approval For Enalapril - Bitget
Sunshine Biopharma receives Canadian approval for generic enalapril By Investing.com - Investing.com Canada
Sunshine Biopharma receives Canadian approval for generic enalapril - Investing.com
Sunshine Biopharma Receives Canadian Regulatory Approval for Enalapril, Expanding Into $25.94 Billion Global Anti-Hypertensive Drug Market - Eagle-Tribune
EXCLUSIVE: Sunshine Biopharma Secures Canadian Approval for Generic Hypertension Drug - Yahoo Finance
Sunshine (SBFM) Quarterly Performance Check: The Company Lists Its Latest Available Figures in the Reported Period; Session Reaction: The Stock Ends Up 1.79% in the Latest ReadingEarnings Momentum Score - vinanet.vn
101,973 Common Stock of Sunshine Biopharma, Inc. are subject to a Lock-Up Agreement Ending on 18-AUG-2026. - marketscreener.com
Sunshine Biopharma earnings beat by $0.05, revenue topped estimates - Investing.com
SBFM Q1 2026 Earnings: Clinical-Stage Biotech Posts $0.25 Per-Share Loss as Shares Slip 4.17%Revenue Warning Signal - vinanet.vn
SBFM Q1 2026 Earnings: Reported Loss of $0.25 Per Share as Stock Declines 4.17%Pre-Earnings Setup - Vinanet
Sunshine Biopharma Inc (NASDAQ: SBFM) Share Price, SBFM Stock News, SBFM Share Price & Updates - kalkine.ca
SBFM Q1 2026 Earnings: Net Loss of -$0.25 Per Share as Pre-Revenue Oncology Developer Presses OnForward Guidance Trends - vinanet.vn
L1 Capital (SBFM) discloses 4.99% Sunshine Biopharma stake plus large warrant position - Stock Titan
Sunshine Biopharma (SBFM) investors cap warrant-driven stake at 9.99% - Stock Titan
Sunshine Biopharma Launches Amoxicillin in Canada and Begins Pharmacy Shipments, Targeting an Estimated $4.9 Billion Global Market - The Lawton Constitution
Sunshine Biopharma (SBFM) Holds Gains at $1.23 as Stock Stays Rangebound Between Key LevelsActive ETF Flow - dars.gov.et
SBFM Q1 2026 Earnings: Net Loss of $0.25 Per Share Highlights Pre-Commercial Biotech StageGuidance Downgrade Alert - vinanet.vn
SBFM Stock Holds Support As Traders Eye Next Move - timothysykes.com
SBFM Stock Holds Support As Sunshine Biopharma Tightens Cash Control - StocksToTrade
SBFM Stock Holds Range As Traders Weigh Weak Margins - timothysykes.com
SBFM Stock Slides As Traders Focus On Cash Runway And Volatility - StocksToTrade
SBFM Stock Pops As Health Canada Greenlights New Generics - StocksToTrade
Amoxicillin Market Estimated at $4.9B as Canada Shipments Begin - Stock Titan
Sunshine Biopharma Inc. Revenue Breakdown – NASDAQ:SBFMW - TradingView
SBFM Looks 84.2% Undervalued on GF Value™ Despite Distressed Fun - GuruFocus
Sunshine Biopharma receives Canadian approval for generic dienogest By Investing.com - Investing.com Nigeria
Sunshine Biopharma receives Canadian approval for generic dienogest - Investing.com
Sunshine Biopharma's 2mg Tablet for Endometriosis Pain Wins Canadian Approval - Stock Titan
EXCLUSIVE: Sunshine Biopharma Targets Canadian Market with New Women's Health Drug Approval - Benzinga
SBFM Q2'26 Earnings: EPS estimate is (1.20) USD - TradingView
Sunshine Biopharma Enters the $2.8 Billion Global Dienogest Market with Canadian Regulatory Approval - Yahoo Finance
Sunshine Biopharma wins Canadian approval for generic Dienogest tablets - Bitget
Sunshine Biopharma Inc Azioni (SBFM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.56%
1.43%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):